Warnex has announced its Medical Laboratories division's distribution agreement with Biron-Laboratoire medical, a Quebec-based provider of diagnostic and medical treatment services.
According to the terms of the agreement, Biron will promote and distribute Warnex's test for the influenza A H1N1 virus, specifically targeting industrial companies.
Warnex uses RT-PCR technology to specifically detect the influenza A virus, including the A H1N1 strain.
Warnex provides results in as little as eight hours.
Warnex has also launched a test that specifically detects the H275Y mutation of the pandemic influenza A H1N1 virus, which is associated with resistance to Tamiflu, a drug used for the treatment and prevention of the flu.
